Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

<p>Gene mutation analysis identified in 50 patients with PanNETs</p>

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Junfeng Xu (16437141) (author)
Tác giả khác:	Zeng Ye (16437144) (author), Qifeng Zhuo (16437147) (author), Heli Gao (16437150) (author), Yi Qin (15400233) (author), Xin Lou (16437153) (author), Wuhu Zhang (16437156) (author), Fei Wang (16437159) (author), Yan Wang (16437162) (author), Desheng Jing (16437165) (author), Guixiong Fan (16437168) (author), Yue Zhang (16437171) (author), Xuemin Chen (16437174) (author), Jie Chen (16437177) (author), Xiaowu Xu (16437180) (author), Xianjun Yu (16437183) (author), Shunrong Ji (16437186) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Cancer Biology Clinical Research and Trials Endocrine-Related Cancers Oncogenes & Tumor Suppressors Precision Medicine Rare Cancers
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
Bằng: Junfeng Xu (16437141)
Được phát hành: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
Bằng: Dipika R. Mohan (15011204)
Được phát hành: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Bằng: Clare Vesely (505402)
Được phát hành: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Bằng: Clare Vesely (505402)
Được phát hành: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Bằng: Clare Vesely (505402)
Được phát hành: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Bằng: Clare Vesely (505402)
Được phát hành: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Bằng: Clare Vesely (505402)
Được phát hành: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Bằng: Clare Vesely (505402)
Được phát hành: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
Bằng: Yemin Wang (17315078)
Được phát hành: (2025)

Supplementary fig 1 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Bằng: Jiwei Bai (15051797)
Được phát hành: (2025)

Supplementary fig 2 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Bằng: Jiwei Bai (15051797)
Được phát hành: (2025)

Supplementary fig 3 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Bằng: Jiwei Bai (15051797)
Được phát hành: (2025)

Supplementary fig 4 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Bằng: Jiwei Bai (15051797)
Được phát hành: (2025)

Supplementary fig 5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Bằng: Jiwei Bai (15051797)
Được phát hành: (2025)

Table S1-S5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Bằng: Jiwei Bai (15051797)
Được phát hành: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Bằng: Evangeline R. Jackson (15558808)
Được phát hành: (2025)

العمل بالأكثر والغالب عند الأصوليين: دراسة تطبيقية
Bằng: Al-mutiri, Aloush Khaled
Được phát hành: (2022)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Bằng: Shiyi Yu (17079079)
Được phát hành: (2025)

Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Bằng: Gwo Yaw Ho (14961416)
Được phát hành: (2025)

Spreadsheet index of named bookbinders in the Sotheby's auction catalogues for the sales of the Major John Roland Abbey collection, sold between 1965 and 1989
Bằng: John Hodgson (22668215)
Được phát hành: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Bằng: Alyssa C. Flint (16676029)
Được phát hành: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Bằng: Alyssa C. Flint (16676029)
Được phát hành: (2025)

Video 1_Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report.mp4
Bằng: Shasha Wei (1555588)
Được phát hành: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Bằng: Laura Boucai (15054310)
Được phát hành: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Bằng: John A. Ligon (15024477)
Được phát hành: (2025)

Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx
Bằng: Xiaohu Jin (9618675)
Được phát hành: (2025)

Cannot write session to /tmp/vufind_sessions/sess_7rirn22k9cisl489ik9q0evdja